Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/57502
Title: A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer.
Authors: 
Keywords: 
Mesh: 
Issue Date: 26-Feb-2019
Citation: Eur Urol.2019;(76)1:43-51
Abstract: The European Randomized study of Screening for Prostate Cancer (ERSPC) has previously demonstrated that prostate-specific antigen (PSA) screening decreases prostate cancer (PCa) mortality. To determine whether PSA screening decreases PCa mortality for up to 16yr and to assess results following adjustment for nonparticipation and the number of screening rounds attended. This multicentre population-based randomised screening trial was conducted in eight European countries. Report includes 182160 men, followed up until 2014 (maximum of 16yr), with a predefined core age group of 162389 men (55-69yr), selected from population registry. The outcome was PCa mortality, also assessed with adjustment for nonparticipation and the number of screening rounds attended. The rate ratio of PCa mortality was 0.80 (95% confidence interval [CI] 0.72-0.89, p20ng/ml (9.9% compared with 4.1% in the second round, p Findings corroborate earlier results that PSA screening significantly reduces PCa mortality, showing larger absolute benefit with longer follow-up and a reduction in excess incidence. Repeated screening may be important to reduce PCa mortality on a population level. In this report, we looked at the outcomes from prostate cancer in a large European population. We found that repeated screening reduces the risk of dying from prostate cancer.
PMID: 30824296
URI: https://hdl.handle.net/20.500.12530/57502
Appears in Collections:Hospitales > H. U. Infanta Cristina > Artículos

Files in This Item:
The file with the full text of this item is not available due to copyright restrictions or because there is no digital version. Authors can contact the head of the repository of their center to incorporate the corresponding file.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.